[1] 刘隽湘. 输血疗法与血液制剂[M].北京: 人民卫生出版社, 1996: 214-215.
[2] Brackmann HH, Oldenburg J, Eis-Hubinger AM, et al. Hepatitis A virus infection among the hemophiliapopulation at the Bonn Hemophilia Center[J]. Vox Sang,1994, 67(S1): 3-8.
[3] Mannucci PM, Gdovin S, Gringeri A, et al. Transmission of hepatitis A to patients with hemophilia by factor Ⅷ concentrates treated with organic solvent and detergent to inactivate viruses. The Italian Collaborative Group[J].Ann Intern Med,1994, 120(1): 1-7.
[4] Lawlor E, Johnson Z, Thornton L, et al. Investigation of an outbreak of hepatitis A in Irish haemophilia A patients[J].Vox Sang 1994,67(S1): 18-20.
[5] Soucie JM, Robertson BH, Bell BP, et al. Hepatitis A virus infections associated with clotting factor concentrate in the United States[J].Transfusion,1998, 38(6): 573-579.
[6] Aguilar FC, Lucia CJF, Ferrer TJ, et al. Parvovirus B19 infection in patients with congenital blood coagulation disorders[J].Med Clin,1997, 108(17): 641-646.
[7] Santagostino E, Mannucci PM, Gringeri A, et al. Transmission of parvovirus B19 by coagulation factor concentrates exposed to 100 degrees C heat after lyophilization[J].Transfusion,1997, 37(5): 517-522.
[8] Lefrere JJ, Mariotti M, Thauvin M. B19 parvovirus DNA in solvent/detergent-treated anti-haemophilia concentrates[J].Lancet,1994, 343(8891): 211-212.
[9] Azzi A, Ciappi S, Zakvrzewska K, et al. Human parvovirus B19 infection in hemophiliacs first infused with two high-purity, virally attenuated factor Ⅷ concentrates[J]. Am J Hematol,1992, 39: 228-230.